SS-31 Side Effects and Safety Findings in Published Research

Reviewed for accuracy by the Gorilla Research Labs research team · 2026-07-04

RESEARCH SS-31 Side Effects and Safety Findings in Published Research SS-31, also known as elamipretide, has been evaluated across various clinical and preclinical models to assess its safety profile and tolerability. Current research indicates that while specific adverse events such as injection site reactions have been documented in human trials, the long-term safety profile and effects in diverse populations remain subjects of ongoing investigation. Compound identity: CAS 736992-21-5 · C32H49N9O5 · 639.8 g/mol (verified via PubChem)

The Mechanism: Targeting Cardiolipin

At the center of SS-31 research is its interaction with cardiolipin, a phospholipid essential for the structural integrity and function of the inner mitochondrial membrane ^[1]. In preclinical models, the stabilization of cardiolipin by SS-31 has been observed to influence mitochondrial respiration and electron transport chain efficiency ^[1]. Because this mechanism is fundamental to cellular bioenergetics, researchers have focused on whether modulating this pathway introduces off-target effects or systemic toxicity. In animal models, the compound has been studied for its ability to prevent the peroxidation of cardiolipin, a process often associated with mitochondrial dysfunction ^[1].

Human Clinical Trial Observations

In the context of human clinical trials, researchers have monitored for adverse events to establish the tolerability of the compound. In a randomized, double-blind, placebo-controlled trial involving individuals with primary mitochondrial myopathy, investigators tracked adverse events throughout the study duration ^[2]. The data from this human trial noted that the most frequently reported adverse events were localized injection site reactions, such as erythema or discomfort ^[2]. These findings provide a specific window into the acute tolerability of the compound in a clinical setting ^[2].

Ophthalmological Safety Data

Beyond systemic myopathy research, SS-31 has been investigated for its potential role in ocular health. The ReCLAIM-2 phase 2 trial examined the safety and efficacy of the compound in patients with dry age-related macular degeneration ^[3]. In this human study, researchers reported the incidence of adverse events to assess whether the compound could be safely administered in this population ^[3]. The findings from this trial contribute to the broader body of safety data, though they are specific to the study's design and the patient population involved ^[3].

Regulatory Status and Barth Syndrome

The regulatory landscape for SS-31 provides further context regarding its safety profile. The FDA granted accelerated approval to elamipretide (marketed as Forzinity) for a defined population of patients with Barth syndrome ^[4]. This approval was based on clinical evidence demonstrating an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit in this specific, rare genetic condition ^[4]. This regulatory milestone relies on the safety data gathered during the clinical development program, which characterized the compound’s profile within the context of Barth syndrome’s specific pathology ^[4].

What Remains Unstudied

While clinical trials have provided data on acute adverse events, significant gaps in the research remain. There is currently a lack of published, peer-reviewed data regarding the long-term, chronic safety profile of SS-31 when administered over extended periods beyond the duration of existing clinical trials. Furthermore, the safety and tolerability of the compound in healthy, asymptomatic individuals have not been the primary focus of the cited clinical literature, which instead emphasizes populations with diagnosed mitochondrial or ocular conditions ^[2], ^[3], ^[4]. Additionally, the interaction of SS-31 with various metabolic states or concurrent pharmacological interventions remains largely unmapped in the current literature. Because the compound acts on fundamental mitochondrial pathways, the potential for systemic effects in diverse physiological contexts is an area that requires further exploration to fully characterize the safety profile beyond the conditions currently cited in published trials ^[1], ^[2], ^[3], ^[4].

Frequently asked questions

What are the most commonly reported side effects in human trials? In published human clinical trials, the most frequently observed adverse events have been localized reactions at the site of administration, such as redness or discomfort ^[2], ^[3]. Is SS-31 approved for general use? No. The FDA has granted accelerated approval for elamipretide specifically for a defined population of patients with Barth syndrome ^[4]. Does the research indicate systemic toxicity? The cited studies focus on specific patient populations and do not provide a comprehensive assessment of systemic toxicity in the general population ^[2], ^[3], ^[4]. Have long-term safety studies been conducted? The current body of published research is limited to the durations specified in clinical trials, and there is no extensive data on chronic, long-term safety ^[2], ^[3]. How does the compound interact with other medications? The interaction of SS-31 with other pharmacological agents has not been extensively characterized in the available peer-reviewed literature ^[1], ^[2], ^[3], ^[4]. SS-31 has been evaluated in clinical trials for Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration to characterize its safety and tolerability profile ^[2], ^[3], ^[4]. Research use only. The compounds discussed are supplied for laboratory research and are not for human or veterinary use. Nothing on this page is medical advice, a dosing guide, or a claim about any product sold here; it summarises published research and cites its sources.